Conclusion and future perspectives on antifungal stewardship


Jose Marıa Aguado, Jose Tiago Silva and Emilio Bouza
J Antimicrob Chemother 2016; 71 Suppl 2: ii43–ii44


The term ‘invasive fungal disease’ (IFD) encompasses a wide range of fungal infections, ranging from candidiasis to aspergillosis, and from cryptococcosis to mucormycosis.1 The risk factors and patient populations at risk of developing fungal infections also vary between different fungal species. For example, Aspergillus is more common in patients with haematological malignancies (allogeneic stem cell transplant recipients or patients receiving chemotherapy for acute myeloid leukaemia) and in lung transplant recipients,2 while cryptococcosis is historically associated with patients diagnosed with AIDS.3 Invasive candidiasis (IC) and candidaemia can be considered good examples of the potential pitfalls in the use and misuse of antifungal agents, and also of the limited guidance that is available in how to reduce catheterrelated infections.